Use of HLA-A*11:01-restricted hepatitis B virus (HBV) peptides for identifying HBV-specific CD8+ T cells

A T cell receptor (TCR) molecule comprising a TCR beta chain complementarity determining region 3 (CDR3) comprising an amino acid sequence selected from the group consisting of:

• CASGDSNSPLHF (SEQ ID NO:
• 17), CASSGGQIVYEQYF (SEQ ID NO:
• 18), CSARGGRGGDYTF (SEQ ID NO:
• 19) and CASSQDWTEAFF (SEQ ID NO:
• 20), wherein the TCR molecule is able to bind to a peptide, wherein the peptide comprises an amino acid sequence selected from the group consisting of STLPETAVVRR (SEQ ID NO:
• 21), STLPETAVVR (SEQ ID NO:
• 22), STLPETTVIRR (SEQ ID NO:
• 24), STPPETTVVRR (SEQ ID NO:
• 25), STLPETTVVGR (SEQ ID NO:
• 26) and STIPETTVVRR (SEQ ID NO:
• 27).

A pharmaceutical composition comprising a peptide and a pharmaceutically acceptable carrier, wherein the peptide comprises an amino acid sequence selected from the group consisting of STLPETAVVRR (SEQ ID NO:

• 21), STLPETAVVR (SEQ ID NO:
• 22), STLPETTVTRR (SEQ ID NO:
• 24), STPPETTVVRR (SEQ ID NO:
• 25), STLPETTVVGR (SEQ ID NO:
• 26) and STIPETTVVRR (SEQ ID NO:
• 27), wherein the peptide is less than 30 amino acids long and is capable of binding HLA-A*1101.

A method of treating a Hepatitis B virus infection in an individual, the method comprising administering to the individual an effective amount of a peptide, wherein the peptide comprises an amino acid sequence selected from the group consisting of STLPETAVVRR (SEQ ID NO:

• 21), STLPETAVVR (SEQ ID NO:
• 22), STLPETTVIRR (SEQ ID NO:
• 24), STPPETTVVRR (SEQ ID NO:
• 25), STLPETTVVGR (SEQ ID NO:
• 26) and STIPETTVVRR (SEQ ID NO:
• 27), wherein the peptide is less than 30 amino acids long and is capable of binding HLA-A*1101.